CLINICAL_TRIALS
trial_result
· 2019-11-25
Clinical Trial Update: An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy [Phase 2]
Summary
Open-label extension study assessing safety of PF-06252616 in boys with Duchenne Muscular Dystrophy; terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2019-11-25